- Volume 15 Issue 23
DOI QR Code
Can Megestrol Acetate Induce Thrombosis in Advanced Oncology Patients Receiving Chemotherapy?
- Ordu, Cetin (Department of Medical Oncology, Faculty of Medicine, Bilim University) ;
- Pilanci, Kezban Nur (Department of Medical Oncology, Faculty of Medicine, Bilim University) ;
- Koksal, Ulkuhan Iner (Department of Medical Oncology, Faculty of Medicine, Bilim University) ;
- Okutur, Kerem (Department of Medical Oncology, Faculty of Medicine, Bilim University) ;
- Saglam, Sezer (Department of Medical Oncology, Faculty of Medicine, Bilim University) ;
- Tecimer, Coskun (Department of Medical Oncology, Faculty of Medicine, Bilim University) ;
- Demir, Gokhan (Department of Medical Oncology, Faculty of Medicine, Bilim University)
- Published : 2015.01.06
Background: Megestrol acetate (MA) is a steroid origin medicine often used for control of cachexia in oncologic palliative care. Thrombosis is a common problem in oncology patients. One question is whether MA can cause thrombosis. This retrospective, registry-based analysis was therefore conducted to assess thrombotic processes in oncology patients using MA concurrent with chemotherapy. Materials and Methods: Data on oncology patients at the metastatic stage using MA were obtained from the archives of our center. Outcomes of patients were evaluated for thromboembolic events (VTEs) during treatment. Results: Ninety-seven oncology patients with a median age of 62 (33-84) years were included. During the median follow-up of 17 months, 58 (59.8%) died leaving 39 (31.2%) still alive. Median overall survival (OS) was 19 months (6-180). Mean time of MA use was 8.69 months(
Megestrol acetate;oncology;thrombosis;palliative care;cancer cachexia
- Berenstein EG, Ortiz Z (2005). Megestrol acetate for the treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev, 13, CD004316.
- LaMarr B, Crawford R (2012).Venous thromboembolism and weight changes in veteran patients using megestrol acetate as an appetite stimulant. Federal practitioner, 10, 31-5.
- Blom JW, Doggen CJ, Osanto S, Rosendaal FR (2005). Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA, 293, 715-22. https://doi.org/10.1001/jama.293.6.715
- Blom JW, Vanderschoot JP, Oostindier MJ, et al (2006). Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: Results of a record linkage study. J ThrombHaemost, 4, 529-35. https://doi.org/10.1111/j.1538-7836.2006.01804.x
- Bolen JC, Andersen RE, Bennett RG (2000). Deep vein thrombosis as a complication of megestrol acetate therapy among nursing home residents. J Am Med Dir Assoc, 1, 248-52.
- Bruera E, Macmillan K, Kuehn N, et al (1990). A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer. Cancer, 66, 1279-82. https://doi.org/10.1002/1097-0142(19900915)66:6<1279::AID-CNCR2820660630>3.0.CO;2-R
- Bruera E, Ernst S, Hagen N, et al (1996). Symptomatic effects of megestrol acetate (MA): A double-blind, crossover study. Proc Am Soc Clin Oncol, 15, 531.
- Chew HK, Wun T, Harvey D, et al (2006). Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med, 166, 458-64. https://doi.org/10.1001/archinte.166.4.458
- Chen C, Li G, Liu YD, Gu YJ (2014). A new D-dimer cutoff value to improve the exclusion of deep vein thrombosis in cancer patients. Asian Pac J Cancer Prev, 15, 1655-8. https://doi.org/10.7314/APJCP.2014.15.4.1655
- Cruz JM, Muss HG, Brockschmidt JK, et al (1990). Weight changesin women with metastatic breast cancer treated with megestrol acetate: A comparison of standard versus highdose therapy. Semin Oncol1, 7, 63-7.
- Desport JC, Blanc-Vincent MP, Delabaere G, et al (2000). Standard, options, recommendations (SOR) pour l'utilisation des medicaments orexige nes en cance rologie. Bull Cancer, 87, 315-28.
- Heit JA (2008). The epidemiology of venous thromboembolism in the community. Arterioscler Thromb Vasc Biol, 28, 370-2. https://doi.org/10.1161/ATVBAHA.108.162545
- Heit JA, Silverstein MD, Mohr DN, et al (2000). Risk factors for deepvein thrombosis and pulmonary embolism: A population-based case-control study. Arch Intern Med, 160, 809-15. https://doi.org/10.1001/archinte.160.6.809
- Khorana AA (2010). Venous thromboembolism and prognosis in cancer. Thromb Res, 125, 490-3. https://doi.org/10.1016/j.thromres.2009.12.023
- Khorana AA (2012). Cancer-associated thrombosis: updates and controversies. Hematology Am Soc Hematol Educ Program, 2012, 626-30.
- Khorana AA, Dalal M, Lin J, Connolly GC (2013). Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer, 119, 648. https://doi.org/10.1002/cncr.27772
- Abrams JS, Cirrincione C, Aisner J, et al (1992). A phase III doseresponsetrial of megestrol acetate (MA) in metastatic breast cancer. Proc Am Soc Clin Oncol, 11, 56.
- Aleem A, Al Diab AR, Alsaleh K, et al (2012). Frequency, clinical pattern and outcome of thrombosis in cancer patients in Saudi Arabia. Asian Pac J Cancer Prev, 13, 1311-5. https://doi.org/10.7314/APJCP.2012.13.4.1311
- Khorana AA, Francis CW, Culakova E, Lyman GH (2005). Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer, 104, 2822. https://doi.org/10.1002/cncr.21496
- Kuderer NM, Ortel TL, Francis CW (2009). Impact of venous thromboembolism and anticoagulation on cancer and cancer survival. J Clin Oncol, 27, 4902-11. https://doi.org/10.1200/JCO.2009.22.4584
- Loprinzi CL, Ellison NM, Schaid DJ, et al (1990). Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J Natl Cancer Inst, 82, 1127-32. https://doi.org/10.1093/jnci/82.13.1127
- Loprinzi CL, Michalak JC, Schaid DJ, et al (1993). Phase III evaluation of four doses of megestrol acetate as therapy for patients with canceranorexia and/or cachexia. J Clin Oncol, 11, 762-67.
- Mandala M, Falanga A, Roila F (2011). Management of venous thromboembolism (VTE) in cancer patients: ESMO clinical practice guidelines. Ann Oncol, 22, 85-92.
- Maltoni M, Nanni O, Scarpi E, et al (2001). High-dose progestins for the treatment of cancer anorexia-cachexia syndrome: A systematic review of randomised clinical trials. Ann Oncol, 12, 289-300. https://doi.org/10.1023/A:1011156811739
- Megace [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2012.
- McCarthy HD, Crowder RE, Dryden S, Williams G (1994). Megestrol acetate stimulates food and water intake in the rat: effects on regional hypothalamic neuropeptide Y concentrations. Eur J Pharmacol, 265, 99-102. https://doi.org/10.1016/0014-2999(94)90229-1
- Morley J, Thomas DR, Wilson MM (2006). Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr, 83, 735-43.
- Norleena P. Gullett, Vera Mazurak, Gautam Hepbar, Thomas R. Ziegler (2012). Nutritional interventions for cancer-induced cachexia. Curr Probl Cancer, 35, 58-90.
- Oberhoff C, Hoffmann O, Winkler UH, Schindler AE (2001). Hemostatic effects of high-dose megestrol acetate therapy in patients with advanced gynecological cancer. Gynecol Endocrinol, 15, 341-8. https://doi.org/10.1080/gye.15.5.341.348
- Otten HM, Mathijssen J, Ten Cate H, et al (2004). Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon. Arch Intern Med, 164, 190-4. https://doi.org/10.1001/archinte.164.2.190
- Parnes HL, Conaway M, Aisner J, et al (1999). Megestrol acetate for the treatment of cachexia in patients with advanced lung or colorectal cancers. Cancer Ther, 2, 75-82.
- Ruiz Garcia V, Lopez-Briz E, Carbonell Sanchis R, et al (2013). Megestrol acetate for treatment of anorexia-cachexia syndrome (Review). Cochrane Database Syst Rev, 3, CD004310.
- Seng S, Liu Z, Chiu SK, et al (2012). Risk of venous thromboembolism in patientswith cancer treated with cisplatin: A systematic review and meta-analysis. J Clin Oncol, 30, 4416-26. https://doi.org/10.1200/JCO.2012.42.4358
- Seddighzadeh A, Shetty R, Goldhaber SZ (2007). Venous thromboembolism in patients with active cancer. Thromb Haemost, 98, 656-61.
- Sorensen HT, Mellemkjaer L, Olsen JH, et al (2000). Prognosis of cancers associated with venous thromboembolism. N Engl J Med, 34, 1846-50.
- Tchekmedyian NS, Hickman M (1992). Megestrol acetate in cancer anorexia and weight loss. Cancer, 69, 1268-74.
- Tchekmedyian NS, Hickman M, Siau J, et al (1991). Treatment of cancer anorexia with megestrol acetate: Impact on quality of life. Oncology, 5, 119-26.
- Topkan E, Yavuz AA, Ozyilkan O (2007). Cancer cachexia: pathophysiologic aspects and treatment options. Asian Pac J Cancer Prev, 8, 445-51.
- Zhan P, Wang Q, Qian Q, Yu LK (2013). Megestrol acetate in cancer patients with anorexia-cachexia syndrome: a metaanalysis. Transl Cancer Res, 2, 74-9.
- Randomized double-blind clinical trial of combined treatment with megestrol acetate plus celecoxib versus megestrol acetate alone in cachexia-anorexia syndrome induced by GI cancers vol.26, pp.7, 2018, https://doi.org/10.1007/s00520-018-4047-y